First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (checkmate 743): a Multicentre, Randomised, Open-Label, Phase 3 Trial
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz Kowalski,Jeronimo Rodriguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gerard Zalcman The Lancet（2021）
AI 理解论文
溯源树
样例
